Skip to content
Back to skills

Tooluniverse Structural Proteomics

ASecurity

Structural biology plus proteomics integration for drug target validation. Combines PDB experimental structures, AlphaFold predictions, GPCRdb, SAbDab antibody structures, ProteinsPlus binding-site prediction, and BindingDB ligand-affinity data. Use for druggability assessment, binding-site characterization, ligand-pocket analysis, structural-confidence scoring (resolution, pLDDT), and antibody-target interface analysis.

  • 1,719 stars
  • 0 votes
  • 0 copies
  • 2 views
  • Added September 12, 2026
ai-agentspythongobashdatabase

Security analysis

A100/100

Scanned September 23, 2026

npx -y skills add mims-harvard/ToolUniverse --skill tooluniverse-structural-proteomics --agent claude-code

Installs into .claude/skills of the current project.

Are you the author of Tooluniverse Structural Proteomics?

Add the live security badge to your README. It updates with every re-scan.

Security grade badge for Tooluniverse Structural Proteomics
[![Security: A — Skills Directory](https://www.skillsdirectory.com/api/skills/mims-harvard-tooluniverse-structural-proteomics/badge)](https://www.skillsdirectory.com/skills/mims-harvard-tooluniverse-structural-proteomics)

More formats (shields.io, HTML) on the badges page. Keep it an A: scan every change in CI with Pro.

Download with Pro
SKILL.md
---

name: tooluniverse-structural-proteomics
description: "Structural biology plus proteomics integration for drug target validation. Combines PDB experimental structures, AlphaFold predictions, GPCRdb, SAbDab antibody structures, ProteinsPlus binding-site prediction, and BindingDB ligand-affinity data. Use for druggability assessment, binding-site characterization, ligand-pocket analysis, structural-confidence scoring (resolution, pLDDT), and antibody-target interface analysis."
---

# Structural Proteomics for Drug Target Validation

Comprehensive structural data integration using ToolUniverse tools across PDB, AlphaFold, GPCRdb, SAbDab, and proteomics databases for drug target validation.

## LOOK UP DON'T GUESS

- PDB structures/resolutions: `PDBeSIFTS_get_best_structures` and `RCSBGraphQL_get_structure_summary`
- AlphaFold confidence: `alphafold_get_summary`
- Ligands/affinities: `PDBe_get_structure_ligands` and `BindingDB_get_ligands_by_uniprot`
- Protein-protein binding mutations (ddG): `SKEMPI_search_by_structure`/`SKEMPI_search_by_protein`/`SKEMPI_get_mutation` -- BindingDB's protein-protein equivalent, for interface-mutation affinity effects rather than small-molecule ligands
- Druggability: `ProteinsPlus_predict_binding_sites`

## COMPUTE, DON'T DESCRIBE
When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.

## Domain Reasoning

Resolution determines valid conclusions: <2A = atom positions visible; 2-3A = side chains reliable, drug design supported; >3A = backbone only, binding site unreliable. Do not over-interpret low-resolution structures.

---

## Tool Inventory

### PDB (RCSB)
`RCSBAdvSearch_search_structures` (query_type, query_value, rows), `RCSBData_get_entry` (entry_id), `RCSBGraphQL_get_structure_summary` (pdb_id), `RCSBGraphQL_get_ligand_info` (pdb_id), `RCSB_get_chemical_component` (comp_id)

### PDB (PDBe)
`pdbe_get_entry_summary` (pdb_id), `PDBe_get_structure_ligands` (pdb_id), `PDBe_get_bound_molecules` (pdb_id), `PDBeSearch_search_structures` (query, rows), `PDBeSIFTS_get_best_structures` (uniprot_id), `PDBeSIFTS_get_all_structures` (uniprot_id), `PDBe_KB_get_ligand_sites` (pdb_id), `PDBe_KB_get_interface_residues` (pdb_id), `PDBeValidation_get_quality_scores` (pdb_id)

### PDBe PISA
`PDBePISA_get_interfaces` (pdb_id), `PDBePISA_get_assemblies` (pdb_id)

### AlphaFold
`alphafold_get_prediction` (qualifier=UniProt), `alphafold_get_summary` (qualifier), `alphafold_get_annotations` (qualifier)

### Binding Sites
`ProteinsPlus_predict_binding_sites` (pdb_id, chain), `BindingDB_get_ligands_by_uniprot` (uniprot_id), `BindingDB_get_ligands_by_pdb` (pdb_id), `BindingDB_get_targets_by_compound` (smiles)

### Foldseek
`Foldseek_search_structure` (sequence, mode="tmalign"), `Foldseek_get_result` (ticket)

### GPCRdb
`GPCRdb_get_protein` (protein), `GPCRdb_get_structures` (protein), `GPCRdb_get_ligands` (protein), `GPCRdb_get_mutations` (protein). Accepts entry names, gene symbols (auto-converted to `{symbol.lower()}_human`), or UniProt accessions.

### SAbDab
`SAbDab_search_structures` (query/antigen), `SAbDab_get_structure` (pdb_id), `TheraSAbDab_search_therapeutics` (query), `TheraSAbDab_search_by_target` (target)

### Domains
`InterPro_get_protein_domains` (uniprot_id), `Pfam_get_protein_annotations` (uniprot_id), `UniProt_get_entry_by_accession` (accession)

### Proteomics
`ProteomeXchange_search_datasets` (query), `ProteomeXchange_get_dataset` (dataset_id)

---

## Workflow 1: Find All Structures for a Drug Target

```
Phase 0: Resolve protein → UniProt ID, gene symbol, organism
Phase 1: PDBeSIFTS_get_best_structures → RCSBGraphQL_get_structure_summary → PDBeValidation
Phase 2: alphafold_get_prediction/summary → compare pLDDT with experimental coverage
Phase 3: IF GPCR → GPCRdb; IF antibody target → SAbDab/TheraSAbDab
Phase 4: InterPro/Pfam domain mapping → identify unresolved regions
Phase 5: Summary table (PDB ID, method, resolution, ligands, coverage, quality)
```

**Decisions**: Resolution <2.5A for drug design. X-ray > Cryo-EM > NMR > AlphaFold for binding sites. Holo > apo structures.

## Workflow 2: Identify Binding Pocket Ligands

```
Phase 1: PDBe_get_structure_ligands + RCSBGraphQL_get_ligand_info + PDBe_KB_get_ligand_sites
Phase 2: ProteinsPlus_predict_binding_sites → druggability score, pocket residues
Phase 3: BindingDB_get_ligands_by_pdb/uniprot → Ki, Kd, IC50
Phase 4: RCSB_get_chemical_component for key ligands
```

**Filter artifacts**: GOL, EDO, SO4, PEG, ACT, CL, NA. Keep cofactors (ATP, NAD, HEM) and catalytic metals (ZN, MG) if relevant.

## Workflow 3: Cross-Validate Drug Binding

```
Phase 1: Find co-crystal structures → filter for drug/analogs
Phase 2: BindingDB affinity data (Ki, Kd, IC50)
Phase 3: ProteinsPlus + PDBe-KB binding site characterization
Phase 4: PDBeValidation quality → binding site well-resolved?
Phase 5: AlphaFold + Foldseek structural comparison
Phase 6: GPCR-specific (if applicable) → active/inactive states, pharmacology, resistance mutations
Phase 7: Antibody-specific (if applicable) → epitope mapping
Phase 8: Evidence integration
```

---

## Tool Parameter Gotchas

| Tool | Mistake | Correct |
|------|---------|---------|
| `alphafold_get_prediction/summary` | `uniprot_id` | `qualifier` |
| `GPCRdb_get_protein` | `gene_name` | `protein` |
| `PDBeSIFTS_get_best_structures` | gene symbol | `uniprot_id` (e.g., "P04637") |
| `Foldseek_search_structure` | `mode="3diaa"` | `mode="tmalign"` |
| `SAbDab_search_structures` | `name` | `query` or `antigen` |
| `RCSB_get_chemical_component` | `ligand_id` | `comp_id` |

---

## Evidence Grading

| Tier | Confidence |
|------|------------|
| T1 | Co-crystal (<2.5A) + binding affinity data |
| T2 | Experimental structure + computational prediction |
| T3 | AlphaFold + pocket analysis + known ligand analogs |
| T4 | Homology model or low-resolution only |

## Interpretation

| Metric | High | Acceptable | Caution |
|--------|------|-----------|---------|
| Resolution | <2.0A (X-ray) / <3.0A (cryo-EM) | 2.0-2.5A / 3.0-4.0A | >3.0A / >4.5A |
| R-free | <0.25 | 0.25-0.30 | >0.30 |
| AlphaFold pLDDT | >90 | 70-90 | <70 (disordered) |

DoGSiteScorer >0.6 = druggable; <0.4 = unlikely druggable. PISA assemblies should be cross-validated with SEC-MALS/native MS.

## Limitations

- BindingDB: 60s+ for popular targets
- AlphaFold: lacks ligand context
- GPCRdb: Class A-F GPCRs only
- PDBePISA: `operation` is internal, not a public parameter

Attribution

Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.

Comments

Loading comments…